We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 58 for:    "Anaplastic oligoastrocytoma"

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

This study has been terminated.
(Low accrual rate)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01339039
First Posted: April 20, 2011
Last Update Posted: November 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 8, 2017
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)